evaluated both by a gastroenterologist and by a dermatologist, and we are planning to start ustekinumab soon.
A second patient reported onset of nonbloody diarrhea and abdominal pain after a 5-month therapy with secukinumab for ankylosing spondylitis. A colonoscopy with histological examination showed a segmental chronical inflammation of the bowel, suggestive of IBD. We decided to stop secukinumab administration and to prescribe systemic oral steroids. Three months later the patient was in clinical remission.
Patient 3 was referred to us because of onset of IBD while undergoing secukinumab treatment for psoriasis unresponsive to immunosuppressants and anti-TNF drugs; he was first admitted to another hospital for non-bloody diarrhea, abdominal pain, vomiting, and weight loss; the patient reported starting secukinumab 3 months before the onset of symptoms. Colonoscopy showed extensive colonic inflammation, and histological examination was suggestive of IBD. After stopping secukinumab the patient was treated with adalimumab, with no benefit. Due to the severe activity of both IBD and psoriasis we decided to start ustekinumab, with good results on dermatological and gastroenterological symptoms.
Although IL-17 is believed to be one of the pro-inflammatory cytokines involved in pathogenesis of IBD [2] , a few cases of worsening or new onset of IBD in patients undergoing IL-17A inhibitor therapy have been reported [3, 4] . Moreover, during secukinumab clinical trials on psoriasis, 3 ulcerative colitis (UC) and 1 Crohn's disease (CD) cases were reported among the treatment group (whereas in the placebo group no cases of IBD were detected) [5] .
The IBD incidence seen in these studies may in part be related to the underlying correlation between IBD and psoriasis, psoriatic arthritis, and ankylosing spondylitis, but the possibility that IBD is an adverse effect of the biologic itself cannot be excluded. This arouses important thoughts about the etiopathogenesis of IBD: the complete block of the action of IL-17A could contribute to the leaky intestinal epithelium found in IBD [3] ? 
